(19)
(11) EP 2 783 686 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
04.03.2015 Bulletin 2015/10

(88) Date of publication A3:
01.10.2014 Bulletin 2014/40

(43) Date of publication:
01.10.2014 Bulletin 2014/40

(21) Application number: 14164259.5

(22) Date of filing: 18.02.2002
(51) International Patent Classification (IPC): 
A61K 31/4196(2006.01)
A61P 35/00(2006.01)
A61K 31/502(2006.01)
A61K 31/7068(2006.01)
 A61K 31/436(2006.01)
A61K 31/337(2006.01)
A61K 31/704(2006.01)
A61K 33/24(2006.01)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
LT LV RO SI

(30) Priority: 19.02.2001 GB 0104072
17.10.2001 GB 0124957

(62) Application number of the earlier application in accordance with Art. 76 EPC:
02719864.7 / 1363627

(71) Applicants:
  • Novartis AG
    4056 Basel (CH)

    BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR 
  • Novartis Pharma GmbH
    1230 Wien (AT)

    AT 

(72) Inventors:
  • Lane, Heidi
    4106 Therwill (CH)
  • O'Reilly, Terence
    4057 Basel (CH)
  • Wood, Jeanette Marjorie
    4105 Biel-Benken (CH)

(74) Representative: Kristl, Jernej 
Novartis Pharma AG Patent Department
4002 Basel
4002 Basel (CH)

 
Remarks:
This application was filed on 10-04-2014 as a divisional application to the application mentioned under INID code 62.
 


(54) Combination of a rapamycin derivative and letrozole for treating breast cancer


(57) The disclosure relates to 40 0 (2 hydroxyethyl) rapamycin in combination with letrozole for use in the treatment of breast cancer.